How much is the latest price of a box of Nadimedine in 2025?

Naldimedine is indicated for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain, including chronic pain associated with prior cancer or its treatment, that does not require frequent (e.g., weekly) opioid dose escalations. This article will provide readers with comprehensive and practical information from three aspects: the latest price, global listing status, and medication preparation.

What is the latest price of a box of Nadimedin in 2025?

The price varies depending on the specifications and purchase channels. Pricing information in 2025 is crucial to patient medication planning.

Prices of different specifications

Nadimedine currently comes in two specifications: 0.2mg*50 tablets/box, priced at approximately US$520, and 0.2mg*14 tablets/box, priced at approximately US$173. Patients can choose the appropriate specification based on the treatment cycle and economic conditions.

Price change trend

Compared with previous years, the price of nadimedine in 2025 remained relatively stable and did not fluctuate significantly. However, due to exchange rate changes and regional differences, the actual purchase price may fluctuate slightly.

Purchase Channels and Costs

Nadimedine is not yet available in mainland China, and patients need to purchase it through formal cross-border medical platforms or overseas channels. International shipping and duties are additionally charged at the time of purchase and the total cost may be higher than the listed price.

The price of Nadimedine will remain stable in 2025. Patients should choose the appropriate specifications based on their own medication needs and financial capabilities, and purchase through formal channels to ensure drug quality.

Global marketing status of Naldimedine

The global marketing process of Naldimedine directly affects the drug accessibility for patients in various regions, and understanding its approval status is of important reference value to patients.

Main listing countries

Nadimedine has been approved for marketing in Japan, the United States, the European Union and other countries and regions. Among them, Japan's Shionogi Pharmaceutical is the main manufacturer and was the first to be approved in Japan in 2017.

China’s marketing progress

As of June 2025, naldimedine has not yet received marketing approval from the China National Medical Products Administration, nor has it been included in the medical insurance catalog. Domestic patients need to obtain the drug through cross-border channels.

Current status of generic drugs

Currently, there are no generic drugs of Nadimedine on the market globally, and patients can only choose the original drug. During the patent protection period, the possibility of generic drugs being launched on the market is low.

The global distribution of naldimedine is uneven, and Chinese patients face barriers to medication use. As clinical demand increases, the scope of marketing is expected to be further expanded in the future.

Preparation for taking naldimedine

The correct use of naldimedine requires adequate preparation, including medication evaluation, dosage planning and precautions.

Pre-medication assessment

Before starting treatment, it is necessary to confirm that the patient meets the indication criteria, that is, constipation caused by long-term use of opioids. Also assess liver function and avoid use in patients with severe liver damage.

Dosage and administration

The recommended dose for adults is 0.2 mg once daily, which can be taken with food or on an empty stomach. It should be noted that if opioids are discontinued, naldimedine should be discontinued simultaneously.

Adverse reaction monitoring

Common adverse reactions include abdominal pain, diarrhea and other gastrointestinal symptoms. Monitor for symptoms of opioid withdrawal during treatment, especially in patients with compromised blood-brain barrier.

The standardized use of naldimedine requires close cooperation between doctors and patients, and full control from assessment to medication, in order to ensure maximum treatment effects and reduce risks.